Navigation Links
TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
Date:8/21/2008

NEW YORK, MUNICH, Germany and AMSTERDAM, Netherlands, Aug. 21 /PRNewswire/ -- Paul Capital Healthcare and SpePharm Holding, B.V., the pan-European specialty pharmaceutical company, today announced that they have entered into a euro 10 million revenue interest acquisition financing agreement to fund SpePharm's acquisition of Dantrium(R) for Europe and certain other markets, from Procter & Gamble Pharmaceuticals. At the same time, TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare also announced the closing of a euro 16 million equity financing round to fund the ongoing growth of SpePharm Holding, B.V. SpePharm's senior management will also participate in this current equity financing.

Jean-Francois Labbe, Chief Executive Officer of SpePharm, said:

"We are very pleased and excited by this major step in the development of our company. The investment made by Paul Capital Healthcare and the increased financial commitment of our founding investors TVM Capital and Signet Healthcare Partners will enable SpePharm to accelerate the implementation of its strategy to become a leading pan-European specialty pharmaceutical company. These transactions will provide SpePharm with the resources to complete the build up of our sales and marketing infrastructure, launch and promote our current product portfolio and acquire rights to additional products in areas of therapeutic interest."

Mr. Labbe continued:

"Dantrium is a unique product used to treat malignant hyperthermia, a life-threatening reaction to certain gaseous anesthetics. Dantrium's significant clinical benefit fits perfectly with SpePharm's focus on hospital products that provide substantial medical and economic value. Procter & Gamble has established a solid commercial platform for Dantrium, and we believe that SpePharm has the strategy and resources to enhance the product's commercial and clinical value."

Dr. Ken Macleod, a partner at Paul Capital Healthcare, said
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
2. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
3. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... NextCODE Health, which enables clinicians and researchers to ... today announced the launch of its new genomic data analysis ... American Society of Human Genetics (ASHG) annual meeting in ... and apply for free beta access, visit www.nextcode.com . ... be viewed here . The Exchange: ...
(Date:10/19/2014)... October 19, 2014 The report "Chocolate, ... Share, Trade, Prices, Geography Trend and Forecast (2011 - ... category, and geography and studies the major market drivers, ... America, Europe, and Asia. , The global chocolate market ... $98.3 billion in 2016 at an estimated CAGR of ...
(Date:10/18/2014)... October 19, 2014 The “Human ... Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid ... Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to ... drivers, restraints, challenges, opportunities, current market trends, and ... with the estimates and forecasts of the revenue ...
(Date:10/18/2014)... The Asia-Pacific hardware encryption display market report defines and ... forecast of revenue. This market was valued $5,154.0 million ... by 2018, at a CAGR of 58.4% from 2013 ... Asia-Pacific hardware encryption market report, to get an idea ... glimpse of the segmentation of the market, and is ...
Breaking Biology Technology:The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3
... Complex ... Systems for Type 2 Diabetes, CAMBRIDGE, Mass., April ... identifying molecular mechanisms, networks and,biomarkers to better understand large ... Pharmaceuticals, Inc. (Nasdaq: SIRT ),a biopharmaceutical company focused ...
... Calif., April 30 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... discovery, development and commercialization of,novel small-molecule therapeutics, today ... on Thursday, May 8, 2008 at 11:00 a.m.,ET/8:00 ... first quarter ended,March 31, 2008., Individual and ...
... of Botaneco,s technology to add ... functionality to Echium oil ... TSX symbol: SBS, CALGARY, April 30 /PRNewswire-FirstCall/ ... signed a,feasibility agreement with Croda Enterprise Technology, part of Croda,International Plc, an international ...
Cached Biology Technology:Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award 2Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 2Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 3
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... One of the planet,s leading questions is how to ... increasingly variable climate. The Food and Agriculture Organization of ... 70% over the next 40 years to feed a ... of the necessary rise in food production. Plants—grains, ... by supporting livestock. Current research must tap into ...
(Date:10/14/2014)... – Scientists from The Scripps Research Institute (TSRI) have ... Health (NIH) to lead an investigation of Lassa fever ... Africa. The study aims to understand how Lassa fever ... others survive the inflection. , "The ultimate goal ... how Lassa fever virus causes disease and develop new ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... in the Galpagos, the child abuse "cycle of violence" found in ... Nazca boobies by Wake Forest University researchers provides the first evidence ... are young often grow up to be abusers. The study ... Auk . "We were surprised by the intense interest ...
... House announced Sept. 27 that Lan Yang, PhD, assistant ... of Engineering & Applied Science of Washington University in ... Presidential Early Career Awards for Scientists and Engineers (PECASE). ... bestowed by the United States government on science and ...
... of a $3.6 million federal grant, a Michigan State ... to help middle school girls particularly minority girls ... activity. The five-year Girls on the Move project, ... and funded by the National Institutes of Health, focuses ...
Cached Biology News:Child abuse in birds: Study documents 'cycle of violence' in nature 2WUSTL scientist wins prestigious Presidential Early Career Award 2WUSTL scientist wins prestigious Presidential Early Career Award 3$3.6 million nursing research project promotes exercise for girls 2
... Vector NTI Advance 9.1 ... and highly integrated application ... and molecular biology data ... readily available for export. ...
... 50mM Tris-HCl, pH 7.5, 0.1mM ... 1mM benzamidine, 0.1% 2-mercaptoethanol and ... Phosphatase 2A1) partially purified enzyme ... QSepharose,amino-hexyl agarose, Superdex 200, and ...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... vitro cell labeling mix, 92.5 ... solution stabilized with 0.1% 2-mercaptoethanol ... 3,4-dicarboxylic acid. *Amino acid mixture ... containing l-[35S]Methionine and l-[35S]Cysteine. * ...
Biology Products: